Overview: Hemophilia A B VWD Mutation TestIntroduction: The Hemophilia A B VWD Mutation Test detects mutations in genes for hemophilia A, B, or von Willebrand disease, causing excessive bleeding or bruising. Following 2023 ASH guidelines, it uses PCR for high specificity, aiding in genetic screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in molecular pathology for patients with suspected bleeding disorders.
Other Names: Hemophilia/VWD Genetic Assay, Bleeding Disorder Mutation Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Genetic testing for hemophilia began in the 1990s with gene sequencing. PCR advancements in the 2000s improved mutation detection accuracy.
Purpose: Diagnoses hemophilia A, B, or von Willebrand disease, guides treatment, and monitors gene mutations in patients with excessive bleeding or bruising.
Test Parameters: 1. Hemophilia/VWD Mutations
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva at any time. Report symptoms like bleeding or bruising, and list medications.
Specimen: 2-5 mL whole blood (EDTA), 1-2 buccal swabs (sterile swab), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document bleeding, bruising, or history of hemophilia or VWD. Include current medications, especially clotting factors, and family history.
Consent: Written consent required, detailing the tests purpose, genetic implications, and potential need for targeted therapy or genetic counseling.
Procedural Considerations: Uses PCR to detect mutations in F8, F9, or VWF genes. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Poor DNA quality, contamination, or rare mutations can affect results. Incomplete family history may complicate interpretation.
Clinical Significance: Identified mutations confirm hemophilia A, B, or VWD, guiding factor replacement or other therapies. Negative results may require additional genetic testing.
Specialist Consultation: Consult a hematologist or genetic counselor for result interpretation and management planning.
Additional Supporting Tests: Factor VIII, IX, VWF antigen, or activity assays to confirm bleeding disorder diagnosis.
Test Limitations: Rare mutations may not be detected. Clinical correlation and family history are essential.
References: ASH Hemophilia Guidelines, 2023; Blood, Peyvandi F, 2022.
